Acceptability, Feasibility, and Efficacy Potential of a Multimodal Acceptance and Commitment Therapy Intervention to Address Psychosocial and Advance Care Planning Needs among Anxious and Depressed Adults with Metastatic Cancer by Arch, Joanna J. et al.
Acceptability, feasibility, and efficacy potential of a multi-modal ACT intervention to address psychosocial and 
advance care planning needs among anxious and depressed adults with metastatic cancer 
 
Running title: M-ACT for adults with advanced cancer 
 
Joanna J. Arch*1 2 
Joel N. Fishbein1 
Michelle C. Ferris1 
Jill L. Mitchell3 
Michael E. Levin4 
Elizabeth T. Slivjak1 
David J. Andorsky3 
Jean S. Kutner5 
 
1Department of Psychology and Neuroscience, University of Colorado Boulder, 345 UCB Muenzinger, 
Boulder, CO, 80303-0345, USA 
2Division of Cancer Prevention and Control, University of Colorado Cancer Center, Aurora, CO, 80045, USA 
3Rocky Mountain Cancer Centers-Boulder, Boulder, CO, USA 
4Department of Psychology, Utah State University, Logan, UT, USA 
5Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, 
Aurora, CO, USA 
 
*Corresponding author: Joanna.Arch@Colorado.edu, phone: 303-492-4634 
                                                                                     M-ACT for adults with advanced cancer 2 
 
Abstract 
Background: Adults with metastatic cancer frequently report anxiety and depression symptoms, which may 
impact health behaviors such as advance care planning (ACP). 
Objective: The study leveraged Acceptance and Commitment Therapy (ACT), an evidence-based approach for 
reducing distress and improving health behaviors, and adapted it into a multi-modal intervention (M-ACT) 
designed to address the psychosocial and ACP needs of anxious and depressed adults with metastatic cancer. 
The study evaluated M-ACT’s acceptability, feasibility, and efficacy potential. 
Design: The study was designed as a single-arm intervention development and pilot trial.  
Setting/Subjects: The trial enrolled 35 anxious or depressed adults with stage IV cancer in community oncology 
clinics, with a referred-to-enrolled rate of 69% and eligible-to-enrolled rate of 95%. 
Measurements: M-ACT alternated four in-person group sessions with three self-paced online sessions. 
Acceptability and feasibility were assessed through enrollment, attendance, and satisfaction ratings. Outcomes 
and theorized intervention mechanisms were evaluated at baseline, mid-intervention, post-intervention, and 2-
month follow-up. 
Results: Participant feedback was used to refine the intervention. Of participants starting the intervention, 92% 
completed, reporting high satisfaction. One-quarter did not begin M-ACT due to health declines, moving, or 
death. Completers showed significant reductions in anxiety, depression, and fear of dying, and increases in ACP 
and sense of life meaning. In this pilot, M-ACT showed no significant impact on pain interference. Increases in 
two of three mechanism measures predicted improvement on 80% of significant outcomes. 
Conclusions: The M-ACT intervention is feasible, acceptable, and shows potential for efficacy in community 
oncology settings; a randomized trial is warranted. 
Keywords: Acceptance and Commitment Therapy; Advance Care Planning; Anxiety; Cancer; Metastatic; 
Depression; Palliative Care; Online
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Introduction 
  
Adults with metastatic cancer often report anxiety and depression symptoms, fear of dying, existential 
distress, and pain-related distress, which have been linked to lower quality of life and decreased survival time.1-3 
To exercise control over their future care, patients with metastatic cancer must engage in advance care planning 
(ACP), which involves “understanding and sharing [one’s] personal values, life goals, and preferences 
regarding future medical care”4 including legally designating and discussing these values, goals, and 
preferences with a healthcare proxy in preparation for the possibility of becoming too ill to speak for oneself. 
Previous interventions address only a limited number of these broad psychosocial and ACP needs,5 require 
regular access to palliative care specialists, of whom there is a serious shortage,6 or target patients in general7, 8 
rather than the anxious or depressed patients most in need of support. Few interventions that do not rely on 
palliative care specialists have targeted this full range of needs and few have focused on metastatic patients with 
elevated anxiety or depression symptoms. This study designed, refined, and piloted a multi-modal primary 
palliative care intervention based on Acceptance and Commitment Therapy (M-ACT), an evidence-based 
approach for reducing distress and improving health behaviors.9 The intervention aimed to address the 
psychosocial and initial ACP needs of adults with metastatic cancer reporting elevated anxiety or depression 
symptoms. 
Adults with advanced cancer often experience declining health, intensive treatment schedules, and 
increasingly limited mobility, making it difficult to participate in lengthy in-person interventions.7, 10 Providing 
support through online platforms could remedy these issues, but trials of online-only interventions for patients 
with cancer have generally shown limited and inconsistent psychological benefits.11 A meta-analysis found that 
online interventions are more efficacious and show higher retention rates when they include provider contact 
and support.12 Further, studies evaluating group and individual formats of the same psychosocial intervention 
for adults with metastatic cancer have highlighted the benefits of group interaction,13 suggesting the importance 
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of face-to-face patient contact. We hypothesized that a blended or multi-modal approach that integrated offline 
and online intervention components,14 specifically, four face-to-face group sessions alternating with three self-
paced online sessions, would reduce barriers to completing lengthy in-person interventions,7, 10 without 
sacrificing in-person connection. Interspersing online sessions with group sessions also holds participants 
accountable for completing the online sessions. While a blended approach has shown efficacy in reducing fear 
of cancer recurrence (FCR) among early stage cancer survivors,15 to our knowledge this is the first study to 
assess this blended or multi-modal approach for addressing psychosocial and ACP needs of adults with 
metastatic cancer.  
M-ACT promotes forms of coping that predict positive psychosocial outcomes among cancer survivors: 
actively accepting emotions, reducing dominance of distressing thoughts, clarifying values, and committing to 
pursue activities/decisions that reflect values.16, 17 In a small trial of ACT vs. basic cognitive therapy for women 
with late-stage ovarian cancer, ACT led to superior psychosocial outcomes by large effects.18 However, this 
trial provided 12 individual ACT sessions, and a second small trial provided up to 8 individual sessions,19 
requiring intensive resources that impede scalability.  
We thus developed M-ACT to address patient needs in a more efficient manner by including a limited 
number of group sessions, which treats multiple patients at once and synergizes their collective experience, 
together with online sessions and check-ins completed on their own between group sessions. Targeting 
metastatic cancer patients with elevated anxiety or depression symptoms represents a triaging approach that is 
an efficient use of clinic resources. In contrast to previous ACT interventions for cancer survivors with various 
stages of cancer20 or with no current evidence of disease,21 M-ACT included a focus on ACP completion and 
addressed concerns specific to metastatic cancer such as declining health, values regarding end-of-life care, and 
mortality/running out of time to live. Finally, M-ACT was developed and piloted in collaboration with 
community-based oncology care clinics. To further improve scalability within community settings and to serve 
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a broader range of patients, including those with less common forms of cancer, the intervention was designed to 
serve patients with various forms of metastatic cancer (see Methods and Table 1). 
This study also explored intervention mechanisms, defined as the core therapeutic processes that are 
purported to achieve change and thus to predict intervention outcomes.22 Previous research has identified two 
core ACT mechanisms:22, 23 (1) opening up toward internal experience through acceptance and cognitive 
defusion (observing thoughts in a more objective manner), and (2) moving in meaningful life directions by 
clarifying personal values and pursuing activities and decisions that reflect those values.  We thus explored the 
extent to which the M-ACT intervention was associated with change in these core mechanisms, and whether 
change in mechanisms predicted subsequent change in outcomes. 
This study aimed to develop and refine M-ACT in response to participant and provider feedback, and to 
conduct a single-arm pilot trial to assess feasibility, acceptability, and potential for efficacy in anxiety and 
depression symptoms (primary outcomes), ACP, fear of dying, pain interference, and life meaning (secondary 
outcomes), and explore intervention mechanisms.  
 
Methods 
Participants 
Participants (see Table 1) were English-fluent adults who were: (a) 18 years or older, (b) diagnosed with 
Stage IV solid tumor cancer (any type) or incurable, life-threatening hematologic malignancy; and had: (c) an 
Eastern Cooperative Group Performance Status of 0 to 2,24 i.e., physically well enough to participate, (d) 
moderate to severe anxiety or depression symptoms (see Screener). Participants were recruited from Rocky 
Mountain Cancer Centers in Colorado (Supplemental Figure 1); groups were run onsite in four cohorts of 5 to 9 
participants. The University of Colorado Boulder IRB approved the study (protocol #16-0357) and participants 
gave informed consent.  
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Intervention Development and Refinement 
M-ACT content was developed through an iterative process of adaptation from previous ACT 
interventions for anxious post-treatment cancer survivors,21 with new online content and delivery, and a specific 
focus on ACP and concerns related to metastatic disease and end-of-life (e.g., fear of running out of time, 
declining health). We refined M-ACT in response to feedback from stakeholder clinicians (n=11) and 
participants (see Supplement).  
The M-ACT Intervention Delivery and Content 
As outlined in the Supplemental Materials, the final M-ACT intervention consisted of: a) four 
manualized 2-hour group sessions co-led by an onsite oncology social worker and a clinical psychologist 
(X.X.X.), interspersed with: b) three 45-minute self-paced online sessions that participants completed on their 
own, and c) daily 5 to 7-minute online check-ins throughout. Online sessions, programmed in Qualtrics,25 
applied skills learned in group to daily life and to ACP through interactive exercises that dynamically adapted 
content to individual’s values/goals identified earlier in the session or previous sessions. 
Measures 
Screener. Participants were study-eligible if they scored 3+ on either the anxiety or depression symptom 
(anx/dep) scale of the 4-item Patient Health Questionnaire,26 indicating anx/dep in daily life, and 5+ on either a 
0-10 cancer-related anxiety scale or parallel depression scale, indicating anx/dep about cancer. 
Assessments were completed in REDCap1 at baseline (Pre), mid-intervention (after 2nd group), 1-week 
post-intervention (Post) and 2-months post-intervention (FU).  
Outcomes. The primary outcomes were anxiety symptoms and depression symptoms (anx/dep) 
evaluated with the widely used and validated Hospital Anxiety and Depression Scale;28 baseline αs=.81 and .84 
for the anxiety and depression scales. Secondary outcomes included fear of dying, pain interference, sense of 
 
1 REDCap is a secure, widely-used, web-based platform that supports data capture for research studies [27].  
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life meaning, and completion of initial ACP steps. The first three were assessed with the validated Death and 
Dying Distress Scale29 (baseline α=.94), which assesses fear of dying and shows good convergent and 
discriminant validity; the widely-used, validated Rand Short Form Health Survey-36 single-item pain-
interference question,30, 31 which assesses the degree to which pain interferes normal work including housework; 
and the widely-used Functional Assessment of Chronic Illness Therapy-Spirituality32 peace/meaning scale 
(baseline α=.92), which assesses sense of life meaning and inner peace, and shows good convergent and 
discriminant validity and test-retest reliability.33 Three yes/no questions were summed to assess initial ACP 
steps: (1) reflected on your personal values related to advance care planning; (2) identified a health care agent; 
and (3) completed a Medical Durable Power of Attorney form to legally appoint your healthcare agent.  
Mechanisms. The theorized M-ACT mechanism of opening up toward internal experience via 
acceptance and cognitive defusion was assessed with the Experiences Questionnaire-Decentering scale34 (EQ; 
baseline α=.93) which measures acceptance and defusion generally, and the Cancer Acceptance and Action 
Questionnaire35 (baseline α=.90), which measures acceptance/defusion specifically for thoughts and feelings 
about cancer. The theorized M-ACT mechanism of aligning behavior with personal values was assessed with 
the Bulls Eye Values Survey36 (baseline α=.86).  
Acceptability. On the Client Satisfaction Questionnaire,37 modified for M-ACT (e.g., changing 
references to “service” to “program”), at Post (α=.81), we aimed for a mean above 3.00 (Good-Excellent) on the 
0-4 scale, and on the piloted Session Feedback Questionnaire35, aimed for a mean of 4.00 on a “How valuable 
was today’s session for you?” scale with 1=not valuable, 3=somewhat valuable, and 5=extremely valuable. 
Feasibility. The goal was a ≥50% referred-to-enrolled rate and 70% study completion rate through FU.  
Statistical Approach 
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 We analyzed change in outcomes using nested hierarchical linear models (HLM)2 with random 
intercepts and slopes to model change over time and compare Pre vs. Post and FU (see Supplement).  
Results 
Intervention Feasibility and Acceptability 
 Of 51 study-referred patients (by providers, flyers), 35 (69%) enrolled in the study, representing 95% of 
study-eligible patients. Of these 35 enrollees, 26 began the intervention and 24 (69%) completed the 
assessments, including 1 who dropped out of the intervention (Supplemental Figure 1). Participants who began 
the intervention (n=26) completed an average of 3.25 (SD=.68) of 4 group sessions, 2.92 (SD=.28) of 3 online 
sessions, and overall 6.17 (SD=.76) of the 7 group and online sessions together, indicating good feasibility. 
They also completed an average of 3.02 (SD=1.81) of online check-ins per week. For acceptability, the Client 
Satisfaction Questionnaire M=3.29 (SD=.39) and ‘how valuable was this session’ question M=4.57 (SD=.49) 
met or exceeded aims.  
 We analyzed outcomes for all 24 participants with data beyond baseline, see Supplemental Figure 1.  
Outcomes 
As Table 2 presents, anxiety, depression, and sense of life meaning improved significantly over time and 
from Pre to Post/FU (see Supplemental Table 2 for the full models, including intercepts). ACP and fear of dying 
improved significantly over time and from Pre to FU (ACP was discussed toward the end of M-ACT; thus, 
change did not emerge until FU). By FU, 65% completed the three ACP tasks, compared to 29% at baseline. 
Pain interference showed no change. 
Mechanisms 
Among the mechanisms/processes, both measures of acceptance/defusion increased over time 
 
2We report 2-level HLMs as 3-level HLMs showed similar outcomes but did not improve fit, showed little 
clustering, and had few dfs for random intercepts.  
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(decentering marginally, Table 2). We thus focused analyses on these two mechanisms and on outcomes that 
improved significantly from Pre to Post. In mixed models, change in each general defusion/decentering (EQ) 
and cancer-specific acceptance/defusion (AAQc) from Pre to Mid predicted change in anxiety, depression, and 
life meaning from Pre to Post (ps<.001) and change in these outcomes, plus fear of dying, from Pre to FU 
(ps<.001, though Pre to FU life meaning was predicted by decentering only), see Supplement.  
Discussion 
 This study developed and preliminarily evaluated the first known blended online and in-person group 
intervention for anxious and depressed adults with metastatic cancer. Aims included developing the M-ACT 
intervention (for online sessions) or adapting it from previous work (for group sessions), refining intervention 
content in response to participant and provider feedback, and conducting a single-arm pilot trial to assess 
intervention feasibility, acceptability, and potential to impact outcomes and theorized mechanisms.  
Feasibility and Acceptability 
Based on a priori quantitative and behavioral indices, we met or exceeded the study’s feasibility and 
acceptability goals, establishing a foundation for future studies. Nearly all (92%) who began M-ACT finished 
the assessments, showing strong retention relative to previous studies in metastatic cancer;7, 10 by comparison, 
one recent major study comparatively retained 59% by 2-month follow-up of patients who began the 
intervention7 (the same endpoint as the current study). However, one quarter of enrolled participants did not 
begin our intervention, due largely to health declines. In addition to sample size considerations for a larger trial, 
future directions may include telehealth or videoconferencing to better accommodate health declines and a 
briefer enrollment-to-intervention period to minimize illness-related attrition. Finally, participants completed 
online daily check-ins an average of three days/week, suggesting a need to bolster reminders or adjust 
expectations.  
Potential Benefit to Participants 
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Although the study was not fully powered to assess efficacy, the findings suggest M-ACT’s promise for 
improving anxiety, depression, ACP, sense of meaning, and fear of dying, with medium to medium-large effects 
by follow-up. These findings suggest the promise of the M-ACT approach for improving psychological 
symptoms, ACP completion, and existential well-being among anxious and depressed adults with advanced 
cancer. Pain-related interference did not show improvement, perhaps due to limited power, not sufficiently 
assessing or addressing interference, or many reporting that pain worsened along with their cancer during the 
study.  Future studies should be fully powered to examine group differences and develop content that robustly 
addresses pain, or focus on other outcomes.  
Intervention Mechanisms 
Opening toward internal experience through acceptance and cognitive defusion/decentering predicted all 
significant outcomes apart from the ACP checklist, suggesting that this mechanism exerted therapeutic effects. 
This finding is consistent with previous studies of ACT in cancer populations.18, 21 Future studies should 
examine whether improvement in ACP is predicted instead by improved anxiety and depression outcomes, 
which could be linked to patients’ ability and motivation to engage in ACP.  
The finding that values-aligned behavior did not improve significantly over time was unexpected and 
suggests one of three possibilities: (1) M-ACT functioned primarily via other mechanisms such as 
acceptance/defusion, (2) M-ACT allowed participants to maintain their baseline valued behavior over time, 
despite health declines, and such behavior would have otherwise declined, or (3) valued behavior did improve 
but the study was underpowered to detect improvement or employed an insufficient measure. To evaluate 
among these possibilities, future studies should compare M-ACT to another condition within a randomized trial 
and include alternative measures of valued behavior.38  
Conclusions 
 The current study supports M-ACT’s feasibility, acceptability, and potential for improving psychosocial 
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outcomes and ACP for anxious and depressed adults with advanced cancer. A randomized trial to conclusively 
evaluate M-ACT’s effects appears warranted.  
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Table 1. Participant characteristics (n=35) 
Medical Characteristics  
Cancer type  
    Gastrointestinal 25.71% (9/35) 
    Breast 22.86% (8/35) 
    Gynecologic 17.14% (6/35) 
    Prostate 8.57% (3/35) 
    Multiple Myeloma 5.71% (2/35) 
    Lung 5.71% (2/35) 
    Othera 14.29% (5/35) 
ECOG Performance Status  
    Score of 0 11.43% (4/35) 
    Score of 1 60.00% (21/35) 
    Score of 2 28.57% (10/35) 
Sociodemographic characteristics  
    Age (mean) 61.81 (SD=11.94) 
    Female 62.86% (22/35) 
    White, non-Hispanic 90.00% (27/30) 
    Married or partnered 68.18% (15/22)b 
    Have children 81.82% (18/22)b 
    Education (median) 2 year college 
    Household income (median) $31,000 - $40,000 
 ECOG=Eastern Cooperative Performance Group 
a“Other” signifies rare cancers that we did not wish to identify in a small sample 
bSociodemographic data are unavailable for up to n=13 due to attrition before baseline  
data collection (n=3) or error of omitting these sociodemographic questions for Cohort 1 (n=10) 
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Table 2. Outcome and Process Measure Model Findings 
 
 
Linear Slope  Pre vs. Post Pre vs. Follow-up 
 
β  
(SE) 
β  
(SE) 
Effect Size 
(d) 
β  
(SE) 
Effect Size  
(d) 
Outcomes  
Depression 
(HADS-D) 
-.54**  
(.18) 
-1.75**  
(.64) 
.41 
-2.20**  
(.74) 
.51 
Anxiety  
(HADS-A) 
-.62**  
(.17) 
-2.02*  
(.80) 
.56 
-2.36**  
(.68) 
.66 
Advance Care 
Planning checklist 
.40*  
(.20)  
.28  
(.20) 
.48 
.40*  
(.20) 
.72 
Sense of Meaning 
(FACIT-Sp) 
.86***  
(.22) 
2.67**  
(.92) 
.34 
3.09***  
(.88) 
.39 
Fear of Dying 
(DADDS) 
-1.59*  
(.66) 
-3.87  
(2.60) 
.26 
-6.10*  
(2.61) 
.41 
Pain Interference 
(SF-36) 
-.02  
(.07) 
.05  
(.25) .04 
-.09 
(.28) 
.08 
Mechanisms/Processes 
Decentering  
(EQ) 
.65a  
(.35) 
3.39a  
(1.75) 
.42 
2.47a  
(1.35) 
.31 
Psychological 
Flexibility (AAQc) 
-1.31*  
(.54) 
-3.61  
(2.48) 
.22 
-4.42a 
(2.29) 
.27 
Values  
(BEVS) 
.10 
(.08) 
.37 
(.26) 
.25 
.39  
(.29) .27 
Notes: ap<.09; *p<.05; **p<.01; *** p<.001; see Supplement for d approaches. HADS=Hospital Anxiety and 
Depression Scale; EQ=Experiences Questionnaire; FACIT-Sp=Functional Assessment of Chronic Illness Therapy-
Spirituality Meaning/Peace Subscale; AAQc=Cancer Acceptance and Action Questionnaire (lower scores=higher 
flexibility); DADDS=Death and Dying Distress Scale; SF-36=Rand Short Form Health Survey-36; BEVS=Bulls 
Eye Values Survey 
 
 
